In that regard, we evaluated if cytokines (IL-10, TNF-α, IL-6, and IL-1β) proposed by several groups as indicators of a broad range of immunopathological conditions affecting cancer [15–20] could also serve as potential biomarkers to predict ITD+ leukemia relapse. This evidence concerns the gene IL1B and cancer.